A Chief Scientific Officer's Opinion On Clinical Outsourcing

By Ed Miseta, Chief Editor, Clinical Leader

Dr. Kenneth Burhop is the chief scientific officer of Sangart Inc., a biopharmaceutical company that engages in the research, development, and commercialization of oxygen therapeutics. He joined Sangart in January 2011, after serving as the global scientific lead/CSO for Baxter Healthcare’s Medication Delivery division and VP of R&D for Baxter's Biopharmaceutical Technologies business, including the company’s second generation recombinant hemoglobin program. He has authored over forty publications, more than seventy abstracts, several book chapters, and has been invited to speak at various international meetings and symposia, and is a recognized international expert in the field of hemoglobin therapeutics. Williams answers questions such as:

    What are the benefits to outsourcing?

    What metrics do you use to determine if you should outsource?

    What is the biggest negative perception CROs should work to overcome?